Trials / Completed
CompletedNCT06169982
A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes
A Phase 1, Open-Label, Multiple-Dose Study to Investigate Steady-State Pharmacokinetics and Pharmacodynamics During a Euglycemic Clamp of LY3209590 in Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 | Administered SC |
Timeline
- Start date
- 2023-12-07
- Primary completion
- 2024-07-18
- Completion
- 2024-07-18
- First posted
- 2023-12-14
- Last updated
- 2024-09-04
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06169982. Inclusion in this directory is not an endorsement.